GlassScriptPhysician profile
Thomas M Buchanan
NPI 1710162227
$6,241.03
in general payments reported to CMS, 2019-2025
43 companies · $2,231 in 2025
The $2,231 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $321 · 2021: $532 · 2022: $731 · 2023: $711 · 2024: $1,295 · 2025: $2,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $588.51 | 2021-2025 | Rystiggo, Fintepla, Briviact |
| Abbvie INC. | $566.50 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Emd Serono, INC. | $529.51 | 2019-2025 | Mavenclad |
| Pfizer INC. | $494.11 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $312.21 | 2019-2025 | |
| Argenx US, INC. | $292.35 | 2022-2025 | Vyvgart Hytrulo |
| Livanova USA, INC. | $265.80 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $243.07 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $220.40 | 2019-2025 | Ultomiris |
| Biogen, INC. | $200.10 | 2019-2025 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $177.18 | 2019-2024 | Ajovy, Austedo, Austedo Xr |
| Lundbeck LLC | $165.41 | 2022-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $162.95 | 2019-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $148.16 | 2020-2025 | Kisunla, Emgality, Reyvow |
| Genzyme Corporation | $147.06 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.